Helene Finney

Helene Finney

Company: UCB

Job title: Director, Functional Screening


Helene joined UCB (then Celltech) in 1989 and has since gained expertise in a range of antibody technologies. Her PhD studies at UCB in gene therapy generated the first co-stimulation signal inclusive (now termed “second generation”) CAR-T cell constructs. She has led a variety of antibody technology teams & early stage therapeutic antibody discovery projects for oncology, bone, immunology/inflammation & CNS targets.  Helene now leads the UCB Bispecific Target Discovery team; combining cutting edge antibody & screening technology to discover break-through bispecific antibody drugs across multiple therapeutic areas.

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.